A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results

Nathan Clumeck; Jean Michel Molina; Keith Henry; Joseph Gathe; Jürgen K. Rockstroh; Edwin Dejesus; Xuelian Wei; Kirsten White; Marshall W. Fordyce; Martin S. Rhee; Javier Szwarcberg

doi:10.1097/QAI.0000000000000089

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results

Nathan Clumeck, Jean Michel Molina, Keith Henry, Joseph Gathe, Jürgen K. Rockstroh, Edwin Dejesus, Xuelian Wei, Kirsten White, Marshall W. Fordyce, Martin S. Rhee, Javier Szwarcberg

Medicine - Infectious Disease and International Medicine

Research output: Contribution to journal › Letter › peer-review

80 Scopus citations

Original language	English (US)
Pages (from-to)	e121-e124
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	65
Issue number	3
DOIs	https://doi.org/10.1097/QAI.0000000000000089
State	Published - Mar 1 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1097/QAI.0000000000000089

Find It

Find It at U of M Libraries

Cite this

Clumeck, N., Molina, J. M., Henry, K., Gathe, J., Rockstroh, J. K., Dejesus, E., Wei, X., White, K., Fordyce, M. W., Rhee, M. S., & Szwarcberg, J. (2014). A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results. Journal of Acquired Immune Deficiency Syndromes, 65(3), e121-e124. https://doi.org/10.1097/QAI.0000000000000089

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results. / Clumeck, Nathan; Molina, Jean Michel; Henry, Keith et al.
In: Journal of Acquired Immune Deficiency Syndromes, Vol. 65, No. 3, 01.03.2014, p. e121-e124.

Research output: Contribution to journal › Letter › peer-review

Clumeck, N, Molina, JM, Henry, K, Gathe, J, Rockstroh, JK, Dejesus, E, Wei, X, White, K, Fordyce, MW, Rhee, MS & Szwarcberg, J 2014, 'A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results', Journal of Acquired Immune Deficiency Syndromes, vol. 65, no. 3, pp. e121-e124. https://doi.org/10.1097/QAI.0000000000000089

Clumeck N, Molina JM, Henry K, Gathe J, Rockstroh JK, Dejesus E et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results. Journal of Acquired Immune Deficiency Syndromes. 2014 Mar 1;65(3):e121-e124. doi: 10.1097/QAI.0000000000000089

Clumeck, Nathan ; Molina, Jean Michel ; Henry, Keith et al. / A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection : Analysis of week 144 results. In: Journal of Acquired Immune Deficiency Syndromes. 2014 ; Vol. 65, No. 3. pp. e121-e124.

@article{0c0ad4dee480489fbb45f20c15a66e35,

title = "A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results",

author = "Nathan Clumeck and Molina, {Jean Michel} and Keith Henry and Joseph Gathe and Rockstroh, {J{\"u}rgen K.} and Edwin Dejesus and Xuelian Wei and Kirsten White and Fordyce, {Marshall W.} and Rhee, {Martin S.} and Javier Szwarcberg",

year = "2014",

month = mar,

day = "1",

doi = "10.1097/QAI.0000000000000089",

language = "English (US)",

volume = "65",

pages = "e121--e124",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Wolters Kluwer Health",

number = "3",

}

TY - JOUR

T1 - A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection

T2 - Analysis of week 144 results

AU - Clumeck, Nathan

AU - Molina, Jean Michel

AU - Henry, Keith

AU - Gathe, Joseph

AU - Rockstroh, Jürgen K.

AU - Dejesus, Edwin

AU - Wei, Xuelian

AU - White, Kirsten

AU - Fordyce, Marshall W.

AU - Rhee, Martin S.

AU - Szwarcberg, Javier

PY - 2014/3/1

Y1 - 2014/3/1

UR - http://www.scopus.com/inward/record.url?scp=84894424714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894424714&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000089

DO - 10.1097/QAI.0000000000000089

M3 - Letter

C2 - 24346640

AN - SCOPUS:84894424714

SN - 1525-4135

VL - 65

SP - e121-e124

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - 3

ER -

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 144 results

UN SDGs

Publisher link

Find It

Other files and links

Cite this